Abstract
Background
Association between low counts of herpesvirus-specific T cells and subsequent relapse
of hematologic malignancy has been shown in two retrospective studies.
Methods
Here we present results of a prospective validation study. Multiple subsets of Epstein-Barr
virus (EBV)–specific T cells were measured in 69 patients on day 56 and 84, using
intracellular flow cytometry after incubation of blood mononuclear cells (MNCs) with
EBV peptides or lysate.
Results
All EBV T-cell subsets measured, both on day 56 and 84, were lower in patients who
did versus did not subsequently relapse. This was most significant for day 56 EBV
lysate-stimulated CD8 T cells producing interferon-gamma. Patients with day 56 counts
of this subset >5/µL had a significantly lower likelihood of relapse compared with
those with ≤5/µL (subhazard ratio, 5.7; P = 0.007). Similar significant associations were shown for a total of seven EBV T-cell
subsets on day 56 and nine subsets on day 84. However, sensitivity and specificity
of relapse prediction using the count of any subset was low (area under the curve
of receiver-operator characteristic curve was <0.8).
Discussion
In conclusion, the association between EBV T-cell counts and subsequent relapse is
valid. However, its clinical utility appears to be limited.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Immune cell subset counts associated with graft-versus-host disease.Biol Blood Marrow Transplant. 2014 Apr 1; 20: 450-462
- Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome.Transplantation. 2002 Dec 15; 74: 1551-1559
- Rapid helper T-cell recovery above 200 × 106/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.Bone Marrow Transplant. 2006 Jun 8; 37: 1119-1128
- Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality.Bone Marrow Transplant. 2008 Jan 15; 41: 55-62
- Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.Biol of Blood Marrow Transplant. 2006 Sep 1; 12: 919-927
- High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation.Leukemia. 2012 Feb 29; 26: 359-362
- The interplay between Epstein–Barr virus and B lymphocytes: implications for infection, immunity, and disease.Immunol Res. 2014 May 12; 58: 268-276
- Epstein–Barr Virus Infection.N Engl J Med. 2000 Aug 17; 343: 481-942
- The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.Biol Blood Marrow Transplant. 2010 Apr 1; 16: 509-514
- Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing.Biol Blood Marrow Transplant. 2012 Feb; 18: 295-301
- 1994 Consensus Conference on Acute GVHD Grading.Bone Marrow Transplant. 1995 Jun; 15: 825-828
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report.Biol Blood Marrow Transplant. 2005 Dec; 11: 945-956
- Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.Blood Adv. 2016 Dec 13; 1: 152-159
- Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2016 Sep 1; 22: 1654-1663
- Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.Clin Transplant. 2018 Jan 1; 32: e13150
- Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.Blood. 2014; 123: 3664-3671
- Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2016; 7: 507
- The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.Haematologica. 2010 Oct 1; 95: 1769-1777
- Allo-HLA reactivity of virus-specific memory T cells is common.Blood. 2010 Apr 15; 115: 3146-3157
- In-vitro infection of chronic lymphocytic leukemia cells by Epstein-Barr Virus (EBV).Leuk Res. 1986 Jan 1; 10: 167-177
- Epstein-Barr virus in adult T-cell leukemia/lymphoma.Am J Pathol. 1993 Nov; 143: 1263-1269
- Absence of early HHV‐6 reactivation after cord blood allograft predicts powerful graft‐versus‐tumor effect.Am J Hematol. 2018; (Epub ahead of print)
Article info
Publication history
Published online: June 25, 2019
Accepted:
June 9,
2019
Received:
December 22,
2018
Identification
Copyright
© 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.
